After 120 years of anti-hormonal treatment for breast cancer and more than 50 years since the introduction of tamoxifen, the first targeted therapy in breast cancer, endocrine treatment remains the backbone of adjuvant therapy for ER+/HER2- breast cancer (Figures 1 and 2) [32, 33]. Here, ESR1 is linked to breast carcinoma.